Patents by Inventor Stefan Seeber

Stefan Seeber has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190322748
    Abstract: The invention relates to bispecific antibodies comprising a first antigen-binding site that specifically binds to PD1 and a second antigen-binding site that specifically binds to TIM3, in particular to bispecific antibodies, wherein the bispecific antibody binds to 5 TIM3 with a lower binding affinity when compared to the binding to PD1. The invention further relates to methods of producing these molecules and to methods of using the same.
    Type: Application
    Filed: March 27, 2019
    Publication date: October 24, 2019
    Applicant: Hoffmann-La Roche Inc.
    Inventors: LAURA CODARRI-DEAK, GEORG FERTIG, JENS FISCHER, CHRISTIAN KLEIN, VIKTOR LEVITSKI, VALERIA LIFKE, MARIO PERRO, JOERG THOMAS REGULA, TILMAN SCHLOTHAUER, STEFAN SEEBER, PABLO UMANA, ILDIKO WUENSCHE, ADRIAN ZWICK
  • Publication number: 20190300614
    Abstract: The present invention relates to antibodies against human CSF-1R (anti-CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Application
    Filed: March 25, 2019
    Publication date: October 3, 2019
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Nikolaos DIMOUDIS, Georg FERTIG, Alexander FIDLER, Guy GEORGES, Klaus KALUZA, Martin LANZENDOERFER, Carola RIES, Stefan SEEBER, Marlene THOMAS
  • Patent number: 10336830
    Abstract: The present invention relates to antibodies against human CSF-1R (CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: May 18, 2018
    Date of Patent: July 2, 2019
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Georg Fertig, Alexander Fidler, Klaus Kaluza, Carola Ries, Stefan Seeber, Marlene Thomas
  • Patent number: 10329346
    Abstract: Bispecific tetravalent antibodies against IL-17 and TNFa, useful in therapy, e.g. the treatment of rheumatoid arthritis and other autoimmune diseases and/or to reduce pathological inflammatory conditions.
    Type: Grant
    Filed: February 1, 2016
    Date of Patent: June 25, 2019
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Johannes Auer, Martin Bader, Jens Fischer, Stefan Lorenz, Joerg Moelleken, Stefan Seeber
  • Publication number: 20190185566
    Abstract: The invention relates to novel TNF family ligand trimer-containing antigen binding molecules comprising (a) at least one moiety capable of specific binding to PD1 and (b) a first and a second polypeptide that are linked to each other by a disulfide bond, characterized in that the first polypeptide comprises two ectodomains of a TNF ligand family member or fragments thereof that are connected to each other by a peptide linker and in that the second polypeptide comprises only one ectodomain of said TNF ligand family member or a fragment thereof.
    Type: Application
    Filed: November 13, 2018
    Publication date: June 20, 2019
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Claudia Ferrara Koller, Christina Claus, Christian Klein, Stefan Seeber, Maria Amann, Sandra Grau-Richards, Peter Bruenker, Pablo Umana, Viktor Levitski, Ekkehard Moessner
  • Publication number: 20190153091
    Abstract: Herein is reported a co-cultivation system for co-cultivating a pool of rabbit B-cells or single deposited rabbit B-cells wherein cells CD40L expressing CHO cells are used as feeder in the presence of IL-2 and IL-21.
    Type: Application
    Filed: October 3, 2018
    Publication date: May 23, 2019
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Josef Endl, Jens Fischer, Peter Kern, Sonja Offner, Josef Platzer, Stefan Seeber
  • Patent number: 10287358
    Abstract: The present invention relates to antibodies against human CSF-1R (anti-CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: August 6, 2018
    Date of Patent: May 14, 2019
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Nikolaos Dimoudis, Georg Fertig, Alexander Fidler, Guy Georges, Klaus Kaluza, Martin Lanzendoerfer, Carola Ries, Stefan Seeber, Marlene Thomas
  • Patent number: 10287352
    Abstract: The invention relates to bispecific antibodies comprising a first antigen-binding site that specifically binds to PD1 and a second antigen-binding site that specifically binds to TIM3, in particular to bispecific antibodies, wherein the bispecific antibody binds to TIM3 with a lower binding affinity when compared to the binding to PD1. The invention further relates to methods of producing these molecules and to methods of using the same.
    Type: Grant
    Filed: September 29, 2016
    Date of Patent: May 14, 2019
    Assignee: HOFFMAN-LA ROCHE INC.
    Inventors: Laura Codarri-Deak, Georg Fertig, Jens Fischer, Christian Klein, Viktor Levitski, Valeria Lifke, Mario Perro, Joerg Thomas Regula, Tilman Schlothauer, Stefan Seeber, Pablo Umana, Ildiko Wuensche, Adrian Zwick
  • Publication number: 20190071507
    Abstract: The present invention relates to antibodies against human CSF-1R (anti-CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Application
    Filed: August 6, 2018
    Publication date: March 7, 2019
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Nikolaos DIMOUDIS, Georg FERTIG, Alexander FIDLER, Guy GEORGES, Klaus KALUZA, Martin LANZENDOERFER (DECEASED), Carola RIES, Stefan SEEBER, Marlene THOMAS
  • Publication number: 20190062453
    Abstract: The present invention relates to bispecific antibodies comprising at least one antigen binding site specific for DR5 and at least one antigen binding site specific for FAP, antibodies specific for DR5, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Application
    Filed: March 6, 2018
    Publication date: February 28, 2019
    Applicant: Roche Glycart AG
    Inventors: Peter Bruenker, Sherif Daouti, Ningping Feng, Claudia Ferrara Koller, Guy Georges, Sandra Grau-Richards, Ralf Hosse, Christian Klein, Maximiliane Koenig, Joerg Moelleken, Ekkehard Moessner, Huifeng Niu, Kathryn E. Packman, Valeria Runza, Stefan Seeber, Pablo Umana, lnja Waldhauer, Huisheng Wang, Barbara Weiser
  • Publication number: 20180346582
    Abstract: The present invention relates to antibodies against human CSF-1R (CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Application
    Filed: May 18, 2018
    Publication date: December 6, 2018
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Georg Fertig, Alexander Fidler, Klaus Kaluza, Carola Ries, Stefan Seeber, Marlene Thomas
  • Publication number: 20180328920
    Abstract: Herein is reported a method for the determination of the simultaneous binding of a bispecific antibody to a first and a second antigen comprising the steps of a) incubating a cell expressing cell-membrane bound FRET-donor-tagged first antigen and FRET-acceptor-tagged second antigen with the bispecific antibody, and b) determining the simultaneous binding of the bispecific antibody by determining the energy transfer from the FRET-donor to the FRET-acceptor.
    Type: Application
    Filed: March 30, 2018
    Publication date: November 15, 2018
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Stefan SEEBER, Jens FISCHER, Georg FERTIG
  • Publication number: 20180326054
    Abstract: The invention relates to bispecific antibodies comprising a first antigen binding domain that specifically binds to PD1 and a second antigen binding domain that specifically binds to LAG3. The invention further relates to methods of producing these molecules and to methods of using the same.
    Type: Application
    Filed: April 3, 2018
    Publication date: November 15, 2018
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Laura Codarri Deak, Jens Fischer, Sabine Imhof-Jung, Christian Klein, Stefan Seeber, Patrick Alexander Aaron Weber
  • Publication number: 20180326011
    Abstract: The present invention generally relates to immunoconjugates, particularly immunoconjugates comprising a mutant interleukin-2 polypeptide and a bispecific antigen binding molecule that binds to PD-1 and Tim-3. In addition, the invention relates to polynucleotide molecules encoding the immunoconjugates, and vectors and host cells comprising such polynucleotide molecules. The invention further relates to methods for producing the mutant immunoconjugates, pharmaceutical compositions comprising the same, and uses thereof.
    Type: Application
    Filed: April 2, 2018
    Publication date: November 15, 2018
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Laura Codarri Deak, Christian Klein, Laura Lauener, Stefan Seeber, Pablo Umana, Inja Waldhauer
  • Publication number: 20180326010
    Abstract: The present invention generally relates to immunoconjugates, particularly immunoconjugates comprising a mutant interleukin-2 polypeptide and an antibody that binds to PD-1. In addition, the invention relates to polynucleotide molecules encoding the immunoconjugates, and vectors and host cells comprising such polynucleotide molecules. The invention further relates to methods for producing the mutant immunoconjugates, pharmaceutical compositions comprising the same, and uses thereof.
    Type: Application
    Filed: April 2, 2018
    Publication date: November 15, 2018
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Laura Codarri Deak, Christian Klein, Laura Lauener, Valeria G. Nicolini, Stefan Seeber, Pablo Umana, Inja Waldhauer
  • Patent number: 10093714
    Abstract: Herein is a fusion polypeptide with the formula R1-FC-R2, wherein R1 denotes a first Fc-receptor, R2 denotes a second Fc-receptor, and FC denotes a heavy chain Fc-region polypeptide, wherein R1 or R2 or both are present, wherein FC does not substantially bind to R1 and/or R2 and uses thereof.
    Type: Grant
    Filed: June 4, 2018
    Date of Patent: October 9, 2018
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Petra Rueger, Tilman Schlothauer, Stefan Seeber
  • Publication number: 20180265564
    Abstract: Herein is a fusion polypeptide with the formula R1-FC-R2, wherein R1 denotes a first Fc-receptor, R2 denotes a second Fc-receptor, and FC denotes a heavy chain Fc-region polypeptide, wherein R1 or R2 or both are present, wherein FC does not substantially bind to R1 and/or R2 and uses thereof.
    Type: Application
    Filed: June 4, 2018
    Publication date: September 20, 2018
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Petra Rueger, Tilman Schlothauer, Stefan Seeber
  • Patent number: 10077314
    Abstract: The present invention relates to antibodies against human CSF-1R (anti-CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: January 19, 2018
    Date of Patent: September 18, 2018
    Inventors: Nikolaos Dimoudis, Georg Fertig, Alexander Fidler, Klaus Kaluza, Martin Lanzendoerfer, Carola Ries, Stefan Seeber, Marlene Thomas
  • Patent number: 10072087
    Abstract: The present invention relates to antibodies against human CSF-1R (anti-CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: September 11, 2018
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Nikolaos Dimoudis, Georg Fertig, Alexander Fidler, Guy Georges, Klaus Kaluza, Martin Lanzendoerfer, Carola Ries, Stefan Seeber, Marlene Thomas
  • Publication number: 20180244788
    Abstract: The present invention relates to antibodies against human CSF-1R (anti-CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Application
    Filed: January 19, 2018
    Publication date: August 30, 2018
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Nikolaos DIMOUDIS, Georg FERTIG, Alexander FIDLER, Klaus KALUZA, Marlene THOMAS, Carola RIES, Stefan SEEBER, Martin LANZENDOERFER (DECEASED)